Zobrazeno 1 - 4
of 4
pro vyhledávání: '"gamma Poisson shrinkage"'
Autor:
David Smith, Robert Reynolds, Marsha A. Raebel, Douglas Roblin, Margaret J. Gunter, Lisa Herrinton, Pamala A. Pawloski, Denise Boudreau, Susan E. Andrade, K. Arnold Chan, Taliser R. Avery, Robert L. Davis, Martin Kulldorff, Andrew Bate, Fang Zhang, Inna Dashevsky, Kenneth R. Petronis, Jeffrey S. Brown
Publikováno v:
Pharmaceutics, Vol 5, Iss 1, Pp 179-200 (2013)
Background: Drug adverse event (AE) signal detection using the Gamma Poisson Shrinker (GPS) is commonly applied in spontaneous reporting. AE signal detection using large observational health plan databases can expand medication safety surveillance. M
Externí odkaz:
https://doaj.org/article/8eb7d379bd084f9c9bcdc9bae0c49e43
Autor:
Robert L. Davis, Douglas W. Roblin, K. Arnold Chan, Jeffrey S. Brown, Martin Kulldorff, David H. Smith, Denise M. Boudreau, Inna Dashevsky, Robert F. Reynolds, Lisa J. Herrinton, Taliser R. Avery, Pamala A. Pawloski, Andrew Bate, Kenneth R. Petronis, Margaret J. Gunter, Marsha A. Raebel, Susan E. Andrade, Fang Zhang
Publikováno v:
Pharmaceutics, Vol 5, Iss 1, Pp 179-200 (2013)
Pharmaceutics; Volume 5; Issue 1; Pages: 179-200
Pharmaceutics
Pharmaceutics; Volume 5; Issue 1; Pages: 179-200
Pharmaceutics
Background: Drug adverse event (AE) signal detection using the Gamma Poisson Shrinker (GPS) is commonly applied in spontaneous reporting. AE signal detection using large observational health plan databases can expand medication safety surveillance. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4fcf482941bc0a3e64034865ddf2b45
https://doi.org/10.3390/pharmaceutics5010179
https://doi.org/10.3390/pharmaceutics5010179
Autor:
Cerutti, R, Cesana, M, De Amicis, L, Grossi, E, Luciani, D, Stabilini, M, FAGIUOLI, ENRICO RENZO CESARE, STELLA, FABIO ANTONIO
Purpose: To apply and evaluate Bayesian inter-product quantitative methods for signaling an excess of adverse events to specific pharmaceutical products, taking into account sales data as well as other information accessible to a company's drug-monit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1299::c5d2eab14dbe96154751c598eb685a54
http://hdl.handle.net/10281/1176
http://hdl.handle.net/10281/1176
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.